Chirurgie des tumeurs stromales gastro-intestinales (GIST) aux stades localisés et métastatiques

Translated title of the contribution: Surgical treatment of primary and advanced gastrointestinal stromal tumours (GIST)

S. Bonvalot, D. Rouquié, D. Vanel, J. Domont, A. Le Cesne

Research output: Contribution to journalArticle

Abstract

Treatment options have evolved rapidly since the discovery of imatinib, which selectively inhibits KIT. Complete resection without rupturing the tumour remains the mainstay of treatment in patients with localized, resectable disease. Rupturing the tumour during resection results in a high risk of local recurrence and should be avoided. It is not recommended to include laparoscopy or lymphadenectomy as standard procedures. Metastatic risk is determined based on tumour size and mitotic count. Imat inib is currently being tested as an adjuvant therapy after the resection of high-risk primary GIST. Imatinib is the first successful systemic therapy for patients with metastatic or unresectable disease. The role of secondary surgery in patients treated with imatinib has not yet been defined, although secondary surgery could benefit patients with advanced primary localized tumours amenable to surgery after imatinib therapy or patients with tumour necrosis accompanied by bleeding and localized progression (to avoid life-threatening complications). For the majority of other metastatic residual lesions, future studies are needed to evaluate the potential benefit since progression-free survival is similar to that reported in non-surgical patients.

Translated title of the contributionSurgical treatment of primary and advanced gastrointestinal stromal tumours (GIST)
Original languageFrench
Pages (from-to)102-106
Number of pages5
JournalOncologie
Volume9
Issue number2
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Gastrointestinal stromal tumour
  • GIST
  • Imatinib
  • Sarcoma
  • Surgery

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Surgical treatment of primary and advanced gastrointestinal stromal tumours (GIST)'. Together they form a unique fingerprint.

  • Cite this